422 related articles for article (PubMed ID: 11459319)
21. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis.
Martínez M; López-Ribot JL; Kirkpatrick WR; Bachmann SP; Perea S; Ruesga MT; Patterson TF
J Antimicrob Chemother; 2002 Mar; 49(3):515-24. PubMed ID: 11864952
[TBL] [Abstract][Full Text] [Related]
22. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients.
Chryssanthou E; Torssander J; Petrini B
Scand J Infect Dis; 1995; 27(4):391-5. PubMed ID: 8658076
[TBL] [Abstract][Full Text] [Related]
23. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.
Ruhnke M; Eigler A; Tennagen I; Geiseler B; Engelmann E; Trautmann M
J Clin Microbiol; 1994 Sep; 32(9):2092-8. PubMed ID: 7814530
[TBL] [Abstract][Full Text] [Related]
24. Biotypes of oral Candida albicans isolated from AIDS patients and HIV-free subjects in Thailand.
Teanpaisan R; Nittayananta W; Chongsuvivatwong V
J Oral Pathol Med; 2000 May; 29(5):193-9. PubMed ID: 10801035
[TBL] [Abstract][Full Text] [Related]
25. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).
Zida A; Yacouba A; Bamba S; Sangare I; Sawadogo M; Guiguemde T; Kone S; Traore LK; Ouedraogo-Traore R; Guiguemde RT
J Mycol Med; 2017 Dec; 27(4):469-475. PubMed ID: 28754462
[TBL] [Abstract][Full Text] [Related]
26. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?
Kovacicova G; Krupova Y; Lovaszova M; Roidova A; Trupl J; Liskova A; Hanzen J; Milosovic P; Lamosova M; Macekova L; Szovenyiova Z; Purgelova A; Obertik T; Bille J; Krcmery V
J Infect Chemother; 2000 Dec; 6(4):216-21. PubMed ID: 11810569
[TBL] [Abstract][Full Text] [Related]
27. In vitro susceptibility and sterol biosynthesis of Candida albicans strains after long-term treatment with azoles in HIV-infected patients.
Hundt W; Hofmann H
Infection; 1994; 22(2):124-31. PubMed ID: 8070926
[TBL] [Abstract][Full Text] [Related]
28. [Clinical fluconazole and itraconazole resistance of oro-gastrointestinal candidiasis in a patient with AIDS].
Tebbe B; Boyvat A; Geilen CC; Wölfer LU; Seibold M; Orfanos CE
Hautarzt; 1996 Feb; 47(2):136-9. PubMed ID: 8868459
[TBL] [Abstract][Full Text] [Related]
29. Low levels of antigenic variability in fluconazole-susceptible and -resistant Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Lopez-Ribot JL; McAtee RK; Kirkpatrick WR; La Valle R; Patterson TF
Clin Diagn Lab Immunol; 1999 Sep; 6(5):665-70. PubMed ID: 10473514
[TBL] [Abstract][Full Text] [Related]
30. The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients.
Redding SW; Kirkpatrick WR; Dib O; Fothergill AW; Rinaldi MG; Patterson TF
Spec Care Dentist; 2000; 20(5):178-81. PubMed ID: 11203894
[TBL] [Abstract][Full Text] [Related]
31. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review.
White A; Goetz MB
Clin Infect Dis; 1994 Oct; 19(4):687-92. PubMed ID: 7803633
[TBL] [Abstract][Full Text] [Related]
32. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients.
Patton LL; Bonito AJ; Shugars DA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):170-9. PubMed ID: 11505264
[TBL] [Abstract][Full Text] [Related]
33. Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients.
Nadagir SD; Chunchanur SK; Halesh LH; Yasmeen K; Chandrasekhar MR; Patil BS
Southeast Asian J Trop Med Public Health; 2008 May; 39(3):492-5. PubMed ID: 18564689
[TBL] [Abstract][Full Text] [Related]
34. [Antifungal susceptibility for Candida albicans isolated from AIDS patients with oropharyngeal and esophageal candidiasis: experience with Etest].
Tapia C; González P; Pereira A; Pérez J; Noriega LM; Palavecino E
Rev Med Chil; 2003 May; 131(5):515-9. PubMed ID: 12879812
[TBL] [Abstract][Full Text] [Related]
35. Fluconazole-resistant oral candidosis in a repeatedly treated female AIDS patient.
Thomas-Greber E; Korting HC; Bogner J; Goebel FD
Mycoses; 1994; 37(1-2):35-8. PubMed ID: 7935590
[TBL] [Abstract][Full Text] [Related]
36. The effect of limited exposure to antifungal agents on the germ tube formation of oral Candida albicans.
Ellepola AN; Samaranayake LP
J Oral Pathol Med; 1998 May; 27(5):213-9. PubMed ID: 9682984
[TBL] [Abstract][Full Text] [Related]
37. Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting.
Boerlin P; Boerlin-Petzold F; Goudet J; Durussel C; Pagani JL; Chave JP; Bille J
J Clin Microbiol; 1996 May; 34(5):1235-48. PubMed ID: 8727910
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of resistance to fluconazole in Candida albicans clinical isolates from Iranian HIV-infected patients with oropharyngeal candidiasis.
Salari S; Khosravi AR; Mousavi SA; Nikbakht-Brojeni GH
J Mycol Med; 2016 Mar; 26(1):35-41. PubMed ID: 26627124
[TBL] [Abstract][Full Text] [Related]
39. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis.
Cartledge JD; Midgley J; Gazzard BG
AIDS; 1997 Dec; 11(15):1839-44. PubMed ID: 9412702
[TBL] [Abstract][Full Text] [Related]
40. The impact of polyene, azole, and DNA analogue antimycotics on the cell surface hydrophobicity of Candida albicans and Candida tropicalis in HIV infection.
Anil S; Ellepola AN; Samaranayake LP
Mycopathologia; 2002; 153(4):179-85. PubMed ID: 12014477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
